ImmunityBio (IBRX) Stock Surges 12% Following Bullish Hedge Fund Analysis

Key Takeaways

• Shares of ImmunityBio (IBRX) climbed more than 12% to finish at $8.83 on September 29, 2026.
• The GA-Courtenay Special Situations Fund included ImmunityBio among its leading positions in its second-quarter 2026 investor letter.
• The investment firm projects Anktiva’s yearly addressable market exceeds $5.8 billion, potentially surpassing $43 billion with lung cancer authorization.
• The company recently formed a partnership with Accord Healthcare to distribute Anktiva in 30 international markets.
• ImmunityBio launched a Phase 1b clinical study evaluating N-803 alongside two additional oncology treatments for bladder cancer.

ImmunityBio (IBRX) shares ended trading at $8.83 on September 29, 2026, reflecting a daily increase exceeding 12%. The biotech firm’s equity has advanced more than 11% during the preceding month and surged over 256% across the past twelve months.

ImmunityBio, Inc., IBRX

This impressive performance trajectory has attracted attention from institutional investors seeking promising biotechnology opportunities. Green Ash Partners’ GA-Courtenay Special Situations Fund designated ImmunityBio as a notable position in its second-quarter 2026 communication to stakeholders.

The fund emphasized ImmunityBio’s production infrastructure as central to its investment rationale. The organization possesses the capability to manufacture one million vials annually of Anktiva, its primary therapeutic product, which carries a list price of $35,000 per treatment.

Leveraging this production volume, the fund calculates a yearly addressable revenue opportunity exceeding $5.8 billion based solely on Anktiva’s existing regulatory clearances. The fund additionally noted a 99% trailing gross profit margin for the medication.

Expansion Potential Beyond Current Markets

The investment fund’s revenue projections extend well beyond the $5.8 billion baseline. Anktiva has secured international authorization for lung cancer therapy, and the fund anticipates United States approval could materialize by 2028.

Should regulatory clearance occur, the fund projects the total addressable market might exceed $43 billion annually. This projection incorporates cautious pricing assumptions across indications.

ImmunityBio has maintained an aggressive collaboration strategy. The firm established an alliance with Accord Healthcare aimed at broadening Anktiva availability throughout 30 nations, encompassing the United Kingdom, European Union member states, Norway, Iceland, and Liechtenstein.

Accord plans to deploy over 100 professionals across sales, medical affairs, and marketing functions to support the launch. ImmunityBio simultaneously established an Irish operating entity in Dublin to facilitate European distribution operations.

Founder Patrick Soon-Shiong stated the company’s objective involves expanding Anktiva accessibility by completing a randomized clinical study in BCG-naïve patients. This designation applies to bladder cancer individuals who have not undergone BCG immunotherapy or experienced late relapse following prior treatment.

ImmunityBio additionally obtained European Union authorization for Anktiva when administered with BCG. This regulatory milestone occurred shortly after Saudi Arabian authorities encouraged the organization to submit applications for its recombinant BCG therapy to address treatment supply constraints.

Ongoing Clinical Development

The biotech company maintains ongoing discussions with Saudi regulators regarding Anktiva’s combination with checkpoint inhibitor therapies across various cancer types. Last month, Saudi regulatory bodies granted expedited approval for Anktiva in metastatic non-small cell lung cancer and BCG-unresponsive bladder cancer indications.

Regarding clinical research, ImmunityBio initiated a Phase 1b investigation combining N-803, pembrolizumab, and enfortumab vedotin. This study enrolls patients diagnosed with treatment-naïve metastatic urothelial carcinoma, an advanced bladder cancer variant.

The investigation employs a single-arm design, administering identical drug combinations to all participants. It follows an open-label format, ensuring both medical professionals and patients understand the therapeutic regimen.

The trial received initial submission on October 14, 2025. Documentation was most recently revised on September 21, 2026, suggesting progress toward site activation procedures.

The study remains in preparatory stages and has not commenced patient enrollment. Stakeholders can monitor developments through the ClinicalTrials portal as the research program advances.

ImmunityBio maintains a market capitalization of $9.35 billion. The stock’s 52-week price range extends from $1.95 to $12.43.

The post ImmunityBio (IBRX) Stock Surges 12% Following Bullish Hedge Fund Analysis appeared first on Blockonomi.